ArticleInternational journal of retina and vitreous2025
A pilot study of intraoperative melphalan to prevent recurrent PVR: the IOMPVR study.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundProliferative vitreoretinopathy (PVR) is a major cause of failure in cases of retinal detachment (RD) repair. Intravitreal melphalan, a known inhibitor of cellular proliferation, offers a novel therapeutic approach to reduce PVR recurrence and improve outcomes. We evaluated the safety and efficacy of 5 µg/0.1 ml intravitreal melphalan at the end of pars plana vitrectomy (PPV) before silicone oil (SO) injection in eyes with primary PVR related to rhegmatogenous retinal detachments (RRDs) with a minimal 90-day follow-up period.
methodsThis prospective, cross-sectional, interventional pilot study was conducted at the Department of Ophthalmology of the Federal University of São Paulo in patients with primary RRD and PVR. Patients were included who were aged 18 to 85 years with PVR grade CP2 or worse secondary to RRDs in eyes without having undergone a previous RRD surgery. They underwent PPV + scleral buckle + fluid air exchange followed by intravitreal injection of 5 µg/0.1 ml melphalan (270 mOsm) and SO injection.
resultsSix eyes of six patients were enrolled. Ocular examination and imaging showed no retinal toxicity. The logarithm of the minimum angle of resolution best-corrected visual acuity improved from the mean ± standard deviation preoperatively of 2.11 ± 0.22 to 0.89 ± 0.37 at 30 and to 0.84 ± 0.42 at 90 days postoperative (P < 0.001). Optical coherence tomography identified intraretinal cysts in five of six eyes and outer retinal layer loss in all study eyes. Only one of six eyes developed a recurrent localized RD on day 90 unrelated to recurrent PVR. PVR recurrence was not observed during the study follow-up.
conclusionsIn this pilot study, the preliminary data showed that PPV followed by intravitreal injection of 5 µg/0.1 ml melphalan was not related to ocular toxicity. The absence of PVR recurrence at 3 months follow-up in these complex PVR eyes is an interesting finding that justifies further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.